Associated Papers
A scalable approach to resolving variants of uncertain significance.
Tejura M et al.
Biorxiv : the Preprint Server for Biology, 2026
Genetic mechanisms of resistance to targeted KRAS inhibition.
Diaz BJ et al.
Biorxiv : the Preprint Server for Biology, 2025
Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancer.
Aust O et al.
Science Signaling, 2025
Case report: MEK inhibitor as treatment for multi-lineage mosaic KRAS G12D-associated epidermal nevus syndrome in a pediatric patient.
Dionysiou M et al.
Frontiers in Neurology, 2024
Beyond Structural Bioinformatics for Genomics with Dynamics Characterization of an Expanded KRAS Mutational Landscape.
Ratnasinghe BD et al.
Biorxiv : the Preprint Server for Biology, 2023
Beyond structural bioinformatics for genomics with dynamics characterization of an expanded KRAS mutational landscape.
Ratnasinghe BD et al.
Computational and Structural Biotechnology Journal, 2023
Effects of Noonan Syndrome-Germline Mutations on Mitochondria and Energy Metabolism.
Bajia D et al.
Cells, 2022
Markov State Models and Molecular Dynamics Simulations Reveal the Conformational Transition of the Intrinsically Disordered Hypervariable Region of K-Ras4B to the Ordered Conformation.
Zhang H et al.
Journal of Chemical Information and Modeling, 2022
Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.
Johnson C et al.
Cancer Discovery, 2022
Enhanced interpretation of 935 hotspot and non-hotspot RAS variants using evidence-based structural bioinformatics.
Tripathi S et al.
Computational and Structural Biotechnology Journal, 2022
Non-canonical genomic driver mutations of urethane carcinogenesis.
Li S et al.
Plos One, 2022
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH et al.
Journal for Immunotherapy of Cancer, 2020
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Age-Dependent De Novo Mutations During Spermatogenesis and Their Consequences.
Cioppi F et al.
Advances in Experimental Medicine and Biology, 2019
Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes.
Cirstea IC et al.
Human Molecular Genetics, 2013
Two novel germline KRAS mutations: expanding the molecular and clinical phenotype.
Stark Z et al.
Clinical Genetics, 2012
A Patient with Noonan Syndrome with a KRAS Mutation Who Presented Severe Nerve Root Hypertrophy.
Ando Y et al.
Case Reports in Neurology, 0